GEM 132: HYBN began a Phase I safety and pharmacokinetic trial in the U.K.

Hybridon Inc. (HYBN), Worcester, Mass. Product: GEM 132, a hybrid molecule comprised of a strand of synthetic DNA with a protective cap of modified RNA at each end Indication: Cytomegalovirus Status: ...